–Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies– WALTHAM, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Lisa von Moltke, M.D., as its Head of Research and Development and Chief Medical Officer (CMO). Dr. von Moltke brings over 30 years of U.S. and international drug development experience s

- Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD-19 x FcγRIIb inhibitor of B cell function- -Topline results from Phase 2 Trial in Relapsing Multiple Sclerosis (MoonStone) expected in third quarter 2025- -Topline results from pivotal Phase 3 Trial in Immunoglobulin G4-Related Disease (INDIGO) expected year-end 2025- - Enrollment of Phase 2 Trial in Systemic Lupus Erythematosus (SunStone) expected to be completed in 2025- - Out-licensed greater-China anti-IGF-1R Thyroid Eye Disease programs to Zai Lab - WALTHAM, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmac

WALTHAM, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced management's fireside chat presentation at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 3:00 p.m. ET. A live webcast and archived replay of the Company's presentation can be accessed under "Events and Presentations" in the Investor & Media Relations section of the Zenas BioPharma website. About Zenas BioPharma, Inc. Zenas is a clinical-stage global biopharmaceutica

-Completed initial public offering, raising $258.7 million in gross proceeds, to fund the expanded clinical development of lead product candidate, obexelimab, and support company growth strategy- -Concluded targeted enrollment of Phase 3 INDIGO trial evaluating obexelimab for the treatment of Immunoglobulin G4-Related Disease (IgG4-RD)- -Advancing multiple obexelimab Phase 2 and Phase 3 clinical trials with results expected throughout 2025- WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative

-INDIGO is the largest clinical trial conducted in patients living with IgG4-RD- -Topline INDIGO results expected by the end of 2025- WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the completion of its targeted enrollment for the Phase 3 INDIGO trial of its lead product candidate, obexelimab, for the treatment of patients with IgG4-RD. "With the completion of targeted enrollment in our INDIGO trial, the largest IgG4-RD clinical trial ever con

WALTHAM, Mass, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the Company's participation at the following healthcare investor conferences: Guggenheim's Inaugural Healthcare Innovation Conference on November 12, 2024, in Boston, MAJefferies London Healthcare Conference on November 19, 2024 presentation at 4:00 p.m. to 4:25 p.m. GDT, in LondonCiti's 2024 Global Healthcare Conference on December 3, 2024 presentation at 9:30 a.m. to 10:10 a.m. ET, in Miami, FLEver

WALTHAM, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas"), (NASDAQ:ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced that the underwriters of its previously announced upsized initial public offering of 13,235,294 shares of its common stock, which closed on September 16, 2024, exercised in full their option to purchase an additional 1,985,294 shares at the initial public offering price of $17.00 per share. After giving effect to the full exercise of the underwriters' option to purchase additional shares, which closed on September 1

–Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies– WALTHAM, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Lisa von Moltke, M.D., as its Head of Research and Development and Chief Medical Officer (CMO). Dr. von Moltke brings over 30 years of U.S. and international drug development experience s

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4/A - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

Wedbush initiated coverage of Zenas Biopharma with a rating of Outperform and set a new price target of $35.00

Wolfe Research initiated coverage of Zenas Biopharma with a rating of Outperform and set a new price target of $19.00

H.C. Wainwright initiated coverage of Zenas Biopharma with a rating of Buy and set a new price target of $30.00

Rodman & Renshaw initiated coverage of Zenas Biopharma with a rating of Buy and set a new price target of $34.00

Guggenheim initiated coverage of Zenas Biopharma with a rating of Buy and set a new price target of $45.00

Morgan Stanley initiated coverage of Zenas Biopharma with a rating of Overweight and set a new price target of $40.00

Jefferies initiated coverage of Zenas Biopharma with a rating of Buy and set a new price target of $35.00

Citigroup initiated coverage of Zenas Biopharma with a rating of Buy and set a new price target of $27.00

3 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4/A - Zenas BioPharma, Inc. (0001953926) (Issuer)

4/A - Zenas BioPharma, Inc. (0001953926) (Issuer)

SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)

SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)

SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)

SC 13D - Zenas BioPharma, Inc. (0001953926) (Subject)

SC 13D - Zenas BioPharma, Inc. (0001953926) (Subject)

SC 13D - Zenas BioPharma, Inc. (0001953926) (Subject)

SCHEDULE 13G - Zenas BioPharma, Inc. (0001953926) (Subject)

S-8 - Zenas BioPharma, Inc. (0001953926) (Filer)

10-K - Zenas BioPharma, Inc. (0001953926) (Filer)

8-K - Zenas BioPharma, Inc. (0001953926) (Filer)

8-K - Zenas BioPharma, Inc. (0001953926) (Filer)

8-K - Zenas BioPharma, Inc. (0001953926) (Filer)

S-8 - Zenas BioPharma, Inc. (0001953926) (Filer)

8-K - Zenas BioPharma, Inc. (0001953926) (Filer)